Based on the methodological framework, recurring patterns, and proposed evidence upgrades, here are two formal clinical study protocol synopses tailored to (1) the Neoadjuvant Cohort and (2) the CNS / Brain Metastasis Cohort.
Protocol Synopsis 1: The Neoadjuvant Add-On Trial
Protocol Title: A Phase II, Randomized, Placebo-Controlled Study Evaluating Neoadjuvant Chemo-Immunotherapy With or Without Oral Mebendazole and Ivermectin in Early-Stage, High-Risk Triple-Negative Breast Cancer (TNBC).
Study Phase: Phase II (Randomized, double-blind, 1:1 add-on trial).
Study Rationale: Preclinical models indicate that ivermectin induces immunogenic T-cell infiltration to turn “cold” TNBC tumors “hot,” synergizing with immune checkpoint blockade and chemotherapy. Retrospective case series frequently document pathological complete responses in early-stage TNBC when antiparasitics are combined with standard neoadjuvant regimens. A controlled prospective trial is required to isolate whether the repurposed agents independently improve surgical clearance.
1. Patient Population & Eligibility Criteria
Inclusion Criteria:
Female or male patients aged years.
Biopsy-proven, newly diagnosed, treatment-naïve, non-metastatic, early-stage (Stage II–III) invasive breast carcinoma.
Centrally confirmed Triple-Negative Breast Cancer (ER, PR, and HER2 negative by IHC/ISH).
Mandatory pre-treatment core-needle biopsy with baseline histological grading and Ki-67 proliferation index.
Measurable primary breast lesion confirmed on baseline contrast-enhanced breast MRI.
ECOG Performance Status of 0 or 115.
Adequate baseline organ and marrow function (tested within 14 days of Day 1):
Absolute Neutrophil Count (ANC); Platelets; Hemoglobin.
Total bilirubin (upper limit of normal); ALT and AST.
Serum creatinine or calculated creatinine clearance.
Exclusion Criteria:
Radiographic evidence of distant metastases (Stage IV).
Prior chemotherapy, targeted therapy, radiation, or antiparasitic exposure for the current primary tumor.
Pre-existing peripheral neuropathy.
Active autoimmune disease requiring systemic immunosuppression (aside from standard premedication).
Concomitant use of strong CYP3A4 inhibitors/inducers or veterinary-grade products.
2. Dosing Schedule & Treatment Arms
Control Arm (Standard of Care):
KEYNOTE-522-style neoadjuvant regimen: Carboplatin (AUC 1.5 weekly or AUC 5 q3w) + Paclitaxel ( weekly) + Pembrolizumab ( q3w) for 12 weeks, followed by Doxorubicin or Epirubicin + Cyclophosphamide + Pembrolizumab every 3 weeks for 4 cycles.
Experimental Arm (Standard of Care + Investigational Repurposed Add-On):
Same standard neoadjuvant chemo-immunotherapy backbone, plus:
Oral Ivermectin (Human USP Grade): orally once daily, taken with a meal.
Oral Mebendazole (Human USP Grade): orally three times daily, taken with food to optimize bioavailability.
Schedule: Administered continuously throughout the neoadjuvant phase, pausing 7 days before scheduled definitive breast surgery.
3. Endpoints & Required Diagnostic Modalities
Primary Endpoint: Pathological Complete Response (pCR / ypT0/is ypN0) rate at the time of definitive surgery.
Secondary Endpoints:
Residual Cancer Burden (RCB) index and class distribution (RCB-0, I, II, III) on surgical specimen.
Objective radiological response rate on pre-surgical breast MRI (RECIST v1.1).
Serial circulating tumor DNA (ctDNA) clearance kinetics (Baseline, Week 12, Pre-surgery).
Adverse event incidence and severity graded by CTCAE v5.0 (specifically monitoring for transaminitis, gastrointestinal toxicity, and peripheral neuropathy).
3-Year Event-Free Survival (EFS) and Overall Survival (OS).
Diagnostic & Imaging Cadence:
Baseline: Bilateral breast MRI, diagnostic core biopsy with Ki-67, systemic staging CT/PET-CT, and baseline LFTs/CBC/ctDNA.
Mid-Treatment (Week 12): Interval breast MRI and safety labs.
Pre-Surgery (Week 24): Pre-operative breast MRI and interval ctDNA assay.
Surgery: Standardized specimen sectioning with independent pathology review and formal RCB calculation.
Protocol Synopsis 2: The CNS / Brain Metastasis Cohort
Protocol Title: A Single-Arm, Open-Label Phase II Study Evaluating High-Dose Mebendazole and Ivermectin in Patients with Measurable Brain Metastases or Leptomeningeal Disease from Metastatic Breast Cancer.
Study Phase: Phase II (Open-label, prospective exploratory cohort).
Study Rationale: The blood-brain barrier limits systemic drug penetration into the central nervous system, representing a major therapeutic bottleneck in advanced breast cancer. Preclinical literature highlights the tubulin-binding and microtubule-disrupting properties of benzimidazoles in neuro-oncology, and clinical case series document intracranial regressions and marked volume reductions in breast cancer CNS metastases3. A dedicated prospective cohort using standardized neuro-oncology imaging criteria (RANO-BM) is required to determine true intracranial efficacy.
1. Patient Population & Eligibility Criteria
Inclusion Criteria:
Female or male patients aged years with histologically confirmed metastatic breast cancer (any receptor subtype: ER+/PR+, HER2+, or TNBC).
Documented central nervous system (CNS) metastases (parenchymal brain metastases and/or cytology-confirmed leptomeningeal disease).
At least one measurable parenchymal brain metastasis ( in longest dimension) on contrast-enhanced brain MRI that has not undergone whole-brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS), or that shows unequivocal progression following prior radiation.
Neurologically stable for at least 7 days before Day 1, on a stable or decreasing dose of dexamethasone.
Concomitant stable systemic therapy (e.g., endocrine therapy, HER2-targeted agents, or stable chemotherapy) permitted, provided the systemic disease is not requiring immediate alteration.
Adequate hepatic and renal function:
Serum total bilirubin (or in case of Gilbert’s syndrome or liver metastases).
AST/ALT ( if hepatic metastases are documented).
Serum creatinine.
Exclusion Criteria:
Immediate, life-threatening mass effect or herniation requiring urgent neurosurgical decompression.
Severe, uncontrolled intracranial hemorrhage.
Concurrent administration of veterinary formulations.
Inability to swallow oral capsules or tablets.
2. Dosing Schedule & Treatment Architecture
Investigational Repurposed Regimen:
Oral Mebendazole (Pharmaceutical Grade): orally three times daily ( total), administered with high-fat meals to enhance central nervous system and tissue absorption.
Oral Ivermectin (Pharmaceutical Grade): orally once daily (or divided twice daily with meals).
Cycle Length: 28-day continuous cycles.
Dosing Modifications / Safety Stops:
If Grade 3 transaminitis (ALT/AST ) occurs, withhold until recovery, then resume with a 25% dose reduction.
Development of peripheral sensory neuropathy prompts dose de-escalation.
3. Endpoints & Required Diagnostic Modalities
Primary Endpoint: Intracranial Objective Response Rate (iORR) assessed by independent neuro-radiology review using RANO-BM (Response Assessment in Neuro-Oncology Brain Metastases) criteria.
Secondary Endpoints:
Intracranial Progression-Free Survival (iPFS) and systemic Progression-Free Survival (PFS).
Intracranial Disease Control Rate (iDCR: complete response, partial response, or stable disease sustained for weeks).
Overall Survival (OS) at 6, 12, and 24 months.
Neurological symptom burden and functional status assessed via validated Patient-Reported Outcome (PRO) tools (e.g., EORTC QLQ-C30 and BN20 brain cancer module).
Safety profile and adverse event incidence (CTCAE v5.0).
Optional Exploratory Endpoint: Cerebrospinal fluid (CSF) pharmacokinetic concentrations of mebendazole and ivermectin in consenting patients with an indwelling Ommaya reservoir or requiring clinical lumbar punctures.
Diagnostic & Imaging Cadence:
Baseline: Contrast-enhanced 3D-volumetric Brain MRI (slice thickness ), whole-body CT or PET/CT, and baseline neurological evaluation.
On-Treatment Imaging: Serial brain MRI performed every 8 weeks for the first 6 months, and every 12 weeks thereafter until objective intracranial disease progression3.
Safety Labs: Complete blood counts, comprehensive metabolic panel, and liver function panels (ALT, AST, total bilirubin, alkaline phosphatase) checked on Day 1, Day 15 of Cycle 1, and on Day 1 of every subsequent cycle.
Sources
Details the formal Phase II clinical study protocol synopses for both the Neoadjuvant Add-On TNBC Cohort and the Dedicated CNS / Brain Metastasis Cohort, including inclusion/exclusion criteria, KEYNOTE-522 combination schedules, high-dose mebendazole/ivermectin dosing, and RANO-BM/RCB diagnostic endpoints.
1. Primary Source Documents
Structured Case-Series Analysis (Source for Neoadjuvant & CNS Trial Models): Cancer Advisor | OneDayMD. (2026, September 1). Ivermectin, mebendazole and fenbendazole for breast cancer: A structured case-series analysis of 130 reports. Cancer Advisor. https://cancer.aestheticsadvisor.com/2026/09/ivermectin-mebendazole-fenbendazole-breast-cancer.html (The primary methodological framework establishing the need for prospective neoadjuvant cohorts, surgical residual cancer burden evaluation, dedicated CNS metastasis cohorts, and the shift from anecdotal reporting to formal trial designs).
Comprehensive Case Repository & Dosing Exposure Data: OneDayMD Editorial Team. (2026, November 10). Fenbendazole, ivermectin and mebendazole for cancer: Case series of 800+ case reports (November 2026 update) (F. Yap, Med. Rev.). The Medical Advisor. https://www.onedaymd.com/2024/02/fenbendazole-cancer-success-stories.html (Source for human pharmaceutical dosing exposures, meal-timing bioavailability recommendations, and adverse-event monitoring parameters informing protocol dosing schedules).
2. Clinical Standard-of-Care & Diagnostic Endpoints
Neoadjuvant Chemo-Immunotherapy Standard in TNBC (KEYNOTE-522): Schmid, P., Cortés, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Untch, M., Fasching, P. A., Cardoso, F., Andersen, J., Patt, D., Danso, M., Ferreira, M., … O’Shaughnessy, J. (2020). Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine, 382(9), 810–821. (The benchmark regimen establishing the control arm backbone—carboplatin + paclitaxel + pembrolizumab followed by doxorubicin/epirubicin + cyclophosphamide + pembrolizumab—and expected baseline pCR rates).
Surgical Residual Cancer Burden (RCB) Scoring Methodology: Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Erdogan, L., Patel, R., Azad, N., Morandi, P., Hsu, L., Ross, J. S., Hortobagyi, G. N., & Pusztai, L. (2007). Measurement of residual breast cancer for the calculation of the Residual Cancer Burden (RCB) after neoadjuvant therapy. Journal of Clinical Oncology, 25(28), 4414–4422. (The validated surgical pathology scoring system designated as the key secondary endpoint in the neoadjuvant protocol).
Brain Metastases Response Criteria in Neuro-Oncology (RANO-BM): Lin, N. U., Lee, E. Q., Aoyama, H., Barani, I. J., Baumert, B. G., Brown, P. D., Camidge, D. R., Chang, S. M., Dancey, J., Gaspar, L. E., Harris, G. J. R., Hodi, F. S., Kalkanis, S. N., Linskey, M. E., Macdonald, D. R., Margolin, K., Mehta, M. P., Schiff, D., Soffietti, R., … Wen, P. Y. (2015). Response assessment in neuro-oncology brain metastases (RANO-BM) criteria: A consensus proposal. The Lancet Oncology, 16(6), e270–e278. (The consensus neuro-radiological criteria specified for evaluating intracranial objective response rate [iORR] in the CNS synopsis).
Adverse Event & Toxicity Scale (CTCAE v5.0): National Cancer Institute. (2017). Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. U.S. Department of Health and Human Services, National Institutes of Health. (The standard toxicity scale designated for safety pauses, dose modifications, and transaminitis tracking).
3. Preclinical Mechanisms & Human Tolerability Foundations
Immune Activation & Checkpoint Synergy in TNBC: Draganov, D., Gopalakrishnan, S., et al. (2021). Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. npj Breast Cancer, 7, Article 22. (Preclinical rationale for adding oral ivermectin to pembrolizumab and chemotherapy in triple-negative breast cancer).
Blood-Brain Barrier Penetration & Central Nervous System Efficacy: Bai, R. Y., Staedtke, V., Aprhys, C. M., Gallia, G. L., & Riggins, G. J. (2011). Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-Oncology, 13(9), 974–982. (Foundational translational evidence supporting the selection of mebendazole for central nervous system and intracranial disease targeting).
High-Dose Human Tolerability & Pharmacokinetics: Guzzo, C. A., Furtek, C. I., Porras, A. G., Chen, C., Tipping, R., Clineschmidt, C. M., Sciberras, D. G., Hsieh, J. Y., & Lasseter, K. C. (2002). Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. The Journal of Clinical Pharmacology, 42(10), 1122–1133. (Clinical pharmacokinetic data supporting the safety of escalating daily human doses [up to 0.4–0.6 mg/kg] utilized in the synopses).
Mansoori, S., Fryknäs, M., Alvfors, C., Loskog, A., Larsson, R., & Nygren, P. (2021). A phase 2a clinical study on the safety and efficacy of individualized-dose mebendazole in patients with advanced gastrointestinal cancer. Scientific Reports, 11(1), Article 8981. https://doi.org/10.1038/s41598-021-88433-y (Clinical trial demonstrating the tolerability and safety of high-dose individualized oral mebendazole [e.g., 500 mg TID] in oncology patients).

